January 20, 2010Open Access

Treatment with Monoclonal Antibodies against Clostridium difficile Toxins

Key Points

Key points are not available for this paper at this time.

Abstract

The addition of monoclonal antibodies against C. difficile toxins to antibiotic agents significantly reduced the recurrence of C. difficile infection. (ClinicalTrials.gov number, NCT00350298.)

Treatment with Monoclonal Antibodies against Clostridium difficile Toxins

Key Points

Abstract

Cite This Study